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More than 80% of women with breast cancer are now reported to be using complementary and alternative medicine (CAM)
therapies during conventional treatment. A randomized clinical trial (RCT) of reﬂexology with late stage breast cancer patients
serves as the data source for this article. The purposes were to investigate: (i) reasons for refusal to participate in a RCT of
reﬂexology; (ii) the diﬀerences between those who completed the baseline interview and those who dropped out before baseline;
and (iii) the utility of the Palliative Prognostic Score (PPS) as a prognostic screening tool in minimizing early attrition (before
baseline) from the trial. Eligible women (N = 400) approached at 12 cancer centers in the Midwest had advanced breast cancer,
were onchemotherapy orhormonaltherapy, andhad aPPS of11or less.Comparisonsofthosewho dropped outearly (N =33) to
those who stayed in the trial (N = 240) were carried out using Wilcoxon rank, t-, chi-squared and Fisher’s exact tests. The reasons
of being “too sick” or “overwhelmed” were given by less than 12% of the women who refused to participate. There was a higher
early dropout rate amongblack women compared to other (primarily white) women(P = .01). Cancer recurrence and metastasis,
age, and the PPS were not predictive of early retention of women. Specialized techniques may be needed to ensure black women
remain in the trial once consented. Womenwith advanced disease were likely to enter and remain in the trial despite deterioration
in health.
1.Introduction
Breast cancer is the leading malignancy and the second
cause of cancer-related deaths among women [1]. Symp-
toms related to cancer and its treatment persist for long
periods after diagnosis and treatment and can worsen as
the disease becomes more advanced [2–4]. Symptoms are
the strongest predictors of patients’ overall quality of life
(QOL), particularly among those nearing the end of life [5].
Understandably, many women with advanced breast cancer
are turning to complementary and alternative medicine
(CAM) therapies as supportive care during cancer treatment
[6–8]. Over the last few decades CAM therapies have gained
popularity, and according to a 2007 survey, as many as 80%
of women diagnosed with breast cancer report using CAM
for symptom management and improving their QOL [9].
The challenge to investigating popular CAM therapies
among cancer patients with advanced disease can be recruit-
ment and retention in a randomized clinical trial (RCT)
[10, 11]. With some herbal therapies, recruitment into RCT
may be the greatest challenge since patients who agree to
participate and be randomized may be diﬀerent from those
who refuse [12]. Although there is some debate over how
best to study the eﬃcacy of CAM therapies [12, 13], the RCT
nevertheless remains the gold standard.
The accuracy and usefulness of the ﬁndings from a RCT
of a CAM therapy, like any other clinical trial, are only
as good as the internal and external validities of the trial
itself. Internal validity refers to the validity of inferences
drawn from a study [14]. External validity, on the other
hand, reﬂects the extent to which the ﬁndings from the
study can be generalized. Most important in ensuring the
internal and external validity is the selection of a study
sample representative of the target population [15, 16].
Little is known about the characteristics of non-
participants or early dropouts (those who drop out before
baseline interview, which constitutes the formal initiation
of the trial). The data on those who refuse to partici-
pate are rarely available due to human subject research
guidelines, and therefore this assessment of non-participants2 Evidence-Based Complementary and Alternative Medicine
is restricted to a description of reasons for refusal to
participate. After consenting toparticipate in a CAMtherapy
RCT, some women with advanced breast cancer may drop
out for various reasons related to deterioration in health,
exacerbation of symptoms, or death. A high attrition rate
leads to two concerns: (i) patients who drop out are not
exposed to the intervention and receive no beneﬁt, and
(ii) the internal and external validities of the trial can be
compromised [17, 18] because, due to attrition, the sample
may not be representative of the target population or of the
population of those who can potentially beneﬁt from the
intervention.
A review of the pertinent literature did not reveal any
published research addressing recruitment and attrition
issues in CAM therapy trials. A review of RCTs of Tai Chi
conducted between 1966 and 2007, for example, indicated
lack of adequate reporting of several elements of the trial
design and analysis, speciﬁcally lack of a clear description of
recruitment and absence of attrition analyses [19]. Findings
on recruitment reported from other trials are summarized
in an exemplary review by Lovato et al. [20]. Minorities and
women tend to bemore diﬃculttorecruitincontrolledtrials
than the majority and male participants. However, since the
issuance of National Institutes of Health (NIH) guidelines
for targeted recruitment of women and minorities, some
increase in successful recruitment has been documented
[21].
Factors associated with attrition among non-CAM stud-
ies demonstrate substantial variation, not only in the kind
of disease being studied but also by socio-demographic and
clinical characteristics of the participants. In several studies,
attrition was higher among patients of low socioeconomic
status (SES), with low education, and among racial minori-
ties [22–24]. Age of patients is commonly reported as a
predictor of attrition; however, the direction of the eﬀect of
age is less consistent. Several studies report older patients to
be more likely to drop out, whereas others reported younger
patients to be at greater risk of leaving [25, 26].
Literature suggests that patients’ characteristics such as
functional limitations, poor self-reported health, unstable
health status, cognitive impairment, and major disease, par-
ticularly depression, are found to be signiﬁcantly associated
with attrition [27–32]. In their research, Mihelic et al. [33]
reported ﬁnding sicker patients with a high number of
comorbidities and higher level of illness severity to be more
likely to drop out than those with better health statuses.
Conversely, Bender et al. found the opposite: Patients with
fewer coexisting chronic conditions and lower illness severity
were more likely to drop out compared to sicker patients
[22]. These conﬂicting ﬁndings are likely to be the result of
the diﬀerent nature of interventions and target populations
in these two studies. Therefore, investigation of factors
related to attrition in CAM therapy trials among patients
with advanced disease is warranted, and cancer patients
nearing end of life may be a group with unique dynamics,
making it distinctive from other groups of patients.
In trials with cancer patients nearing end of life, one
of the leading reasons for attrition may be deterioration
in health or death. On the other hand, patients with high
symptom burden may beneﬁt from CAM supportive care
intervention. Due to attrition, typically only baseline data
are available for these patients; these data cannot be used in
rigorous testing of the eﬃcacy of CAM intervention without
making certain assumptions; for example, the assumption
of data missing at random. The assumptions underlying
analyses with missing data are not always veriﬁable in
practice [34]. Therefore, exclusion of patients who are
highly unlikely to survive through the duration of trial may
be necessary to avoid relying on unveriﬁable assumptions
in eﬃcacy testing. A commonly used scale for predicting
survival is the Palliative Prognostic Score (PPS) [35, 36].
It was developed using a sample of 519 hospice-home
care patients, and validated in the populations of patients
withterminalcancerandadvancedcancer[37–39].However,
it is unknown whether better survival probability is associ-
ated with retention in CAM clinical trials.
This article addresses the authors’ current use of the
PPS as one of the inclusion criteria in an ongoing trial of
reﬂexology, a commonly used CAM therapy, among women
with advanced breast cancer. To date, the study has 277
women consented with the target recruitment of 390. This
report is guided by the following research questions, among
women with advanced breast cancer:
( i )W h a ta r et h em o s tf r e q u e n tr e a s o n sf o rr e f u s a lt o
participate in a CAM RCT of reﬂexology?
(ii) Among those who consent, what are the diﬀerences
between those who completed the baseline interview
and those who dropped out before baseline?
(iii) What is the utility of the PPS as a prognostic
screening tool in minimizing attrition from the CAM
RCT of reﬂexology?
We focus on early attrition, that is, attrition before baseline
interviewandrandomization.Factors thatinﬂuenceattrition
before and after randomization may be diﬀerent, as attrition
post-randomization may be due to reasons related to the
intervention protocol or allocation into control group [40].
2.Methods
The study was approved by the Institutional Review Board
of the University and those of each of the 12 participating
medical oncology settings in the Midwest. The sites repre-
sented the standard of care for oncology in the Midwest and
comprised a combination of free-standing cancer treatment
facilities and one comprehensive cancer center.
Eligibility criteria included: (i) being a woman 21 years
of age or older; (ii) having diagnosis of stage III or IV
breast cancer, or initial diagnosis of stage I or II with a later
recurrence or metastasis; (iii) being able to perform basic
activities of daily living; (iv) being cognitively intact and
free of a charted diagnosis of mental illness (the recruiter
reviewed the chart for diagnosis of mental illness and asked
women three cognitive orientation questions, on time, place,
and person); (v) being able to speak and understand the
English language; (vi) having access to a telephone; (vii)Evidence-Based Complementary and Alternative Medicine 3
being able to hear normal conversation; (viii) receiving
chemotherapy or hormonal therapy at intake into the study;
and (ix) having a score of 11 or lower on the Palliative
Prognostic Scorescale. Exclusioncriteria forpatientstoenter
the study included: (i) receiving hospice care at intake; (ii)
residing in a nursing home or similar care facility; (iii) being
bedridden; (iv) regularly using complementary therapies
similar to those used in the protocol (e.g., reﬂexology, foot
massage, pedicure with massage); (v) participating in a new
drug experimental chemotherapy; and (vi) undergoing bone
marrowtransplantation.Nursesemployedattherecruitment
sites were trained to implement the recruitment protocol.
Eligible women were approached, given an explanation of
the trial, and invited to sign an informed consent. For
those who refused to participate, nurses obtained reasons for
refusal. Following consent, enrollment data were collected
from the medical record and a baseline telephone interview
was scheduled. For early dropouts (those who consented
but did not complete baseline interview), attrition reasons
were recorded. Upon completion of baseline interview,
women were randomly allocated to one of the following
three groups: (i) intervention (foot reﬂexology); (ii) placebo
foot treatment; or (iii) control. Women in all three groups
continued to receive standard medical care. The participants
randomized to reﬂexology or placebo foot sessions received
interventionsessionseitherathomeorattheoncologyclinic.
In the latter case, sessions were scheduled at participants’
convenience and were coordinated with the times women
came to clinic for their appointments. This research is based
on data collected before baseline interview and random-
ization. These data were collected from medical records
and are limited by the availability of the information to
demographic and clinical variables. Figure 1 summarizes
the numbers of women who were eligible and approached,
refused, consented, and those who dropped out before
baseline interview. Because the study is still in progress, all
women who were enrolled but whose baseline was pending
were not included in the analysis.
2.1. Measures. Nurse recruiters recorded reasons stated by
those who refused to participate. For those who consented,
we used measures from the medical record in regard to
evaluating attrition.
2.1.1. Demographics. These data included age, race, ethnic-
ity, marital status and employment.
2.1.2. Disease Characteristics. The medical record was also
the source for data on cancer stage, recurrence and metas-
tasis, and goal of therapy (curative, palliative, maintenance,
or other).
2.1.3. Palliative Prognostic Score. The PPS determined the
probability of an advanced cancer patient’s survival over the
next 30 days. The PPS score is based on six factors identiﬁed
as predictive of survival in terminally ill cancer patients and
includes: Clinical Prediction of Survival (CPS), Karnofsky
Performance Status (KPS) [41], anorexia, dyspnea, total
Eligible and approached
N = 400
Attrition N = 33
New patients N = 4
Baseline interview
N = 240
Refused
N = 123
Consented
N = 277
New patients are those whose baseline interview
was scheduled but not completed yet
Figure 1: Flowchart of the study.
white blood cell count (WBC), and lymphocyte percentage.
Each variable is assigned a numeric score and a sum of
the scores is calculated for each patient, which can then
be used to assign patients to one of three risk groups. The
scores potentially range from 0 to 17.5, where a higher score
representspoorperformance.Ascorelessthanorequalto5.5
indicates a 70% chance of surviving for 30 days. If the score
is between 5.6 and 11.0, the chance of survival is 30%–70%,
while a score greater than 11.0 indicates a probability less
than 30% [16]. Since a cutoﬀ of 11 was one of the inclusion
criteria, all patients in this study had a PPS of 11 or less.
Amongthosewhoconsented,attritionwasdeﬁnedbythe
completion status of the baseline interview. After excluding
pending patients, all patients who had not completed
baseline interview for any reason were considered early
dropouts.
2.2. Data Analyses. For those who did not consent, refusal
reasons were tabulated. Among those who consented, com-
parisons of those retained and early dropouts were carried
out on demographics, cancer recurrence and metastasis, and
the PPS. Categorical variables were compared using chi-
squareorFisher’sexacttests.Racecategoriesweregroupedas
black versus other (primarily white with a few Asian, Amer-
ican Indian, or Alaskan women). Marital status was grouped
as married or living with a partner versus not. T-tests were
used for comparisons of variables that were approximately
normally distributed (e.g., age). The Wilcoxon rank test
was performed to compare the distribution of PPS for
early dropouts and those who remained in the trial up to
baselineinterview.AllanalyseswereperformedusingSAS9.1
software [42].
3.Results
Research Question 1. What are the most frequent reasons for
refusal to participate in a CAM RCT of reﬂexology?4 Evidence-Based Complementary and Alternative Medicine
Table 1: List of reasons given for refusal to participate.
Reason for refusal to participate N (%)
Too busy 31 (25.20)
No reason 27 (21.95)
Not interested 22 (17.89)
Foot concerns 10 (8.13)
Other 17 (13.82)
Too sick 6 (4.88)
Overwhelmed by prospect of research 8 (6.50)
Do not like being interviewed 2 (1.63)
W o m e n ’ ss t a t e dr e a s o n sf o rr e f u s a lt op a r t i c i p a t ei nt h e
study are listed in Table 1. Despite advanced disease, the
reasons of being “too sick” or “overwhelmed” were given
by less than 12% of the women who refused to participate.
Disinterestinresearch, explicitlystatedorimplicit(noreason
given) accounted for 40% of refusals.
Research Question 2. Among those who consent, what are
the diﬀerences between those who completed the baseline
interview and those who dropped out before baseline?
Table 2 summarizes the characteristics of those who
consented but dropped out before baseline interview, and
those who completed baseline interview. Even though the
majority ofthesample was white, reﬂectiveofthepopulation
of patients treated at the recruitment sites, there was a
signiﬁcantly higher early dropout rate among black women
compared to other (23.5% versus 10.5%, P = .01). No
diﬀerences between early dropouts and those retained up
to the baseline interview were found on age, employment,
cancer recurrence, metastasis, and goal of therapy. The early
dropout rate among women who were married or living
with a partner was 9.5% versus a 16.9% among those who
were never married, divorced, or separated. However, with
available sample size this diﬀerence was not statistically
signiﬁcant (P = .08).
In this study breast cancer patients were treated either
with chemotherapy or hormonal therapy. Among early
dropouts, 63% received chemotherapy and 37% received
hormonal therapy. In general, chemotherapy is associated
with more acute toxicity than hormonal therapy, which
could lead to higher dropout rate. Due to diﬀerences seen
in dropouts among black women compared to non-black
women, we evaluated the association between treatment and
raceamong early dropouts.Chemotherapywas administered
for 57% of black patients as compared to 65% non-
black patients (Fisher’s exact P-value = .99, not in tables).
Therefore, the higher rate of dropouts seen in black women
cannot be explained by treatment administered.
Of the 33 early dropouts, 10 (30%) were too sick or died,
seven (21%) were too busy and two women stated other
unique personal reasons for attrition. The remaining 42%
of early dropouts changed their mind about participation or
could not be reached via the telephone.
Table 2: Comparison of characteristics of patients who consented
but dropped out early to those who completed intake interview.
Characteristics Early drop-outs
N (%)
Completed
baseline
interview N (%)
P-value
Agea 58.12 (12.66) 57.34 (11.36) .71
Palliative Scorea 0.79 (1.09) 0.76 (1.10) .88
Race .01b
White 25 (75.76) 212 (88.70)
Black 8 (24.24) 23 (9.62)
American Indian
or AlaskanNative 0 (0.00) 1 (0.42)
Asian 0 (0.00) 2 (0.84)
Refused 0 (0.00) 1 (0.42)
Ethnicity .41
Non-Hispanic 32 (96.97) 235 (98.33)
Hispanic 1 (3.03) 3 (1.26)
Refused 0 (0.00) 1 (0.42)
Marital status .08c
Married or living
with a partner 17 (51.52) 162 (67.78)
Divorced/separated 8 (24.24) 28 (11.72)
Never married 3 (9.09) 27 (11.30)
Widowed 4 (12.12) 19 (7.95)
Refused 1 (3.03) 3 (1.26)
Type of employment .72d
Retired 9 (27.27) 59 (24.69)
Part time 6 (18.18) 23 (9.62)
Full time 7 (21.21) 64 (26.78)
Disabled 3 (9.09) 29 (12.13)
Not employed 3 (9.09) 37 (15.48)
Homemaker 4 (12.12) 21 (8.79)
Refused 1 (3.03) 6 (2.51)
Palliative score .92
0 19 (57.58) 131 (54.81)
0.5 0 (0.00) 10 (4.18)
1.0 4 (12.12) 47 (19.67)
1.5 4 (12.12) 12 (5.02)
2.0 2 (6.06) 8 (3.35)
2.5 2 (6.06) 17 (7.11)
3.0 1 (3.03) 4 (1.67)
3.5 0 (0.00) 4 (1.67)
4.0 1 (3.03) 4 (1.67)
5.5 0 (0.00) 2 (0.84)
Metastatic cancer .56
Yes 23 (69.70) 178 (74.48)
No 10 (30.30) 61 (25.52)
Recurrent cancer .36
Yes 13 (39.39) 75 (31.38)
No 20 (60.61) 164 (68.62)Evidence-Based Complementary and Alternative Medicine 5
Table 2: Continued.
Characteristics Early drop-outs
N (%)
Completed
baseline
interview N (%)
P-value
Therapy goals 0.47
Maintenance 11 (33.33) 92 (38.49)
Curative 9 (27.27) 78 (32.64)
Palliative 6 (18.18) 41 (17.15)
Uncertain 7 (21.21) 28 (11.72)
aMean and standard deviation.
bP-value for the comparison between black versus other.
cP-value for the comparison between those married or living with a partner
versus other.
dP-value for the comparison those employed versus those not employed.
Research Question 3. What is the utility of the PPS as a
prognostic screening tool in minimizing attrition from the
CAM RCT of reﬂexology?
When early dropouts were compared to those who
completed baseline interview on PPS, no diﬀerences were
found either in the comparisons of the means or of the
distributions (Table 2). Thus the PPS in the range of 11 or
below has not been found to be predictive of retention in the
reﬂexology trial with advanced breast cancer women.
4.Discussion
This research addressed two issues essential to securing
external validity for a trial of a CAM therapy directed at
improving QOL for women with advanced breast cancer.
First is the assessment of reasons given by women who
refused to participate in a CAM trial or who dropped out
shortly after giving consent and before beginning the trial.
This initial assessment provided information about those
who did not participate in the trial and to whom the ﬁndings
cannot be generalized. Second, those who remain in the
trial were compared to those who drop out early on several
characteristics including the PPS. Such comparisons further
shed light on the generalizability of ﬁndings beyond the
sample of those who complete the study.
Women with advanced breast cancer were likely to
enter the trial, with ∼70% of those approached agreeing
to participate. These ﬁndings are consistent with Boon et
al. [9] who found that more than 80% of women with
breast cancer used CAM therapies and therefore could be
interested in participating in a CAM trial. These ﬁndings
are an indication of women’s interest in supportive care they
may receive from using the CAM therapy reﬂexology for
symptom management during chemotherapy. The high rate
of consent also suggests the external validity of ﬁndings that
canbegeneralizedtothepopulationofwomenwithlatestage
breast cancer.
Those who refused to participatewere not sickerpatients,
but rather those who were not interested in research in
general or in reﬂexology speciﬁcally. The refusals due to
strong preferences that are common in the context of CAM
are reported in the literature [12], however reasons of not
agreeing to be randomized was not stated by women in this
trial. A very small percentage of refusals were due to being
too sick. This ﬁnding supports the external validity of trial
results because women who could potentially beneﬁt from
the intervention agreed to participate.
The ﬁnding of a larger dropout rate among blackwomen
is consistent with results of Fair and colleagues [43]. They
successfully recruited a targeted number of blackwomen to a
noninvasive study of mammography, however black women
were more likely to drop out of the study compared to
their white counterparts with 58% of early dropouts being
black. Clinical recruiters may need to implement specialized
techniques to ensure black women remain in the trial once
consented.
The use of the PPS of 11 or less as one of the
inclusion criteria was informed by the literature suggesting
that poor functional status may be predictive of attrition.
Higher likelihood of dropping out for sicker patients with
higher symptom burden was reported in cancer symptom
management trials prior to randomization [40]. Therefore
the ﬁnding of the PPS not being useful for prediction
of early retention was somewhat unexpected. Karnofsky’s
performance status is one of the components of the PPS,
and because more than 50% of palliative prognostic scores
were zero, the KPS contributed zero to the PPS for more
than half of the patients. However, the cut-oﬀ point for
KPS contribution to the PPS is 30. A patient scored at 30
is severely disabled, requiring considerable assistance with
activities of daily living and frequent medical care. Thus a
patient may be clinically quite ill and yet have low PPS.
Another limitation of the PPS is its reliance on clinician
prediction of survival for approximately 50% of the total
score. Reviews of studies have found that clinician estimates
of survival are generally inaccurate and systematically over-
optimistic [38, 44]. Even though the trial is still in progress
and has not reached the ﬁnal sample size, the ﬁnding that
the PPS was not predictive of early attrition was not due to
insuﬃcient power to detect the diﬀerence, but because the
diﬀerence in PPS was not observed. The eﬀect size for the
diﬀerencesonPPSbetweenthosewhodroppedoutandthose
who stayed was virtually zero, therefore even with larger
sample size, the PPS would not be signiﬁcantly associated
with attrition.
Several limitations of this research should be noted.
While information on additional factors that may be related
to attrition such as socioeconomic status (SES), prior CAM
use, and social support was collected in baseline interview,
women who dropped out before the baseline interview did
not have such data collected. Demographic data collected
from medical records provide proxies for some of these
variables, for example, marital status may reﬂect social
support, and employment status may reﬂect SES. We report
onattritionbeforerandomization;therefore,wedidnotcon-
sider attrition by trial arm. All patients included had a PPS
of 11 or less, thus, the utility of PPS across the range of 11.5–
17.5 in minimizing attrition and securing external validity
of the trial remains open to question. A relatively small
proportion of black women remained in trial to complete
baseline interview. It is unknown what the rate of consent6 Evidence-Based Complementary and Alternative Medicine
was among diﬀerent racial groups as race data was not
available for those who did not consent. Additionally, very
few Hispanic women were enrolled reﬂective of the ethnic
distribution in the population treated at the recruitment
locations.
CAM therapies have not been studied extensively with
RCT designs [45, 46], and the ﬁndings on attrition from
other symptom management trials may or may not apply to
CAM trials. Furthermore, among published RCTs of CAM,
quality of reporting is often not adequate, with insuﬃcient
information about recruitment and retention in particular
[19, 47]. This article is among the ﬁrst to reveal factors
associated with patients’ interest and decisions to remain in
CAM therapy trials.
Knowledge about the reasons for refusal and attrition
of advanced breast cancer patients in trials can inform
inclusion criteria and retention strategies of future CAM
trials. For example, because sicker patients may be attracted
to CAM therapies for symptom management and remain
in the trial despite deterioration in health, exclusions based
o nt h eP P Ss c o r eo fh i g h e rt h a n1 1m a yn o tb ew a r r a n t e d .
Participantrecruitersmaysuccessfullyapproachwomenwith
high symptom burden to oﬀer participation in CAM trials
since the intervention may be beneﬁcial as supportive care
during treatment.
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